Head-to-head evidence
albuterol HFA (Proventil HFA) vs Albuterol sulfate (Armstrong)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Proventil HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
In this trial, Proventil-HFA is the established reference product that the investigational Armstrong's albuterol-HFA is being compared against, rather than the agent under primary evaluation itself, and no results have been posted yet.
Albuterol sulfate (Armstrong)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634517 · Phase 3 · terminated
This is a randomized, quadruple-blind, active-controlled study directly measuring lung function, but the sample size is small for a pediatric population and no results have been posted yet, so the outcome is unknown.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Proventil HFA)'s landscape · Albuterol sulfate (Armstrong)'s landscape